TIDMOCTP
RNS Number : 1324J
Oxford Cannabinoid Tech.Holdings
25 April 2022
25 April 2022
Oxford Cannabinoid Technologies Holdings plc
("OCTP", or the "Company")
Formation of Scientific Advisory Board to Support Clinical
Strategy
Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP, OTCQB:
OCTHF), the pharmaceutical company developing prescription
cannabinoid medicines targeting the US$ multi-billion pain market
is pleased to announce the formation of its Scientific Advisory
Board ("SAB").
With the Company's current focus on the treatment of neuropathic
pain conditions, the composition of the SAB will initially comprise
Professor Robert Dworkin, Professor Anthony Dickenson, and Doctor
Giorgio Lambru, together a team of innovators and clinicians with
an emphasis on linking pre-clinical research, clinical trials and
the care of patients. The SAB will work closely with OCTP's Chief
Scientific Officer, Doctor Valentino Parravicini, to provide
scientific guidance on the Company's strategy and overall approach
to clinical trials. Its initial focus will be to advise on the
design of the Company's upcoming phase 1 clinical trials for
OCT130401 and OCT461201, anticipated in Q4 2022 and Q1 2023
respectively, to help OCTP best address the needs of patients. The
SAB will also help to shape the Company's approach as it looks
beyond phase 1, to phase 2 clinical trials, in patients affected by
debilitating pain conditions.
Professor Robert Dworkin, who has been a consultant to the
Company since November 2021, is a Professor in the departments of
Anesthesiology and Perioperative Medicine, Neurology, and
Psychiatry at the University of Rochester Medical Center School of
Medicine and Dentistry, New York State. He is also a Director of
ACTTION (Analgesic, Anesthetic, and Addiction Clinical Trial
Translations, Innovations, Opportunities, and Networks) a
public-private partnership with the United States Food and Drug
Administration. Professor Dworkin's major research interests are
the methodologic aspects of analgesic clinical trials and the
treatment and prevention of chronic neuropathic and musculoskeletal
pain. Through ongoing studies he is evaluating the research designs
and methods, clinical outcome assessments, and statistical analyses
used in clinical trials of treatments for acute and chronic
pain.
Doctor Giorgio Lambru, who has been a consultant to the Company
since February 2022, is a Consultant Neurologist at Guy's & St
Thomas' NHS Foundation Trust, London, and Honorary Senior Lecturer
at King's College London. Dr Lambru is an expert in headache and
facial pain conditions, including neuropathic pain and general
neurology conditions. He has authored a number of scientific
publications on these conditions and has a clinic dedicated to
complex headache and facial pain disorders.
Professor Anthony Dickenson, who has been a consultant to the
Company since May 2021, is Emeritus Professor of Neuropharmacology
at University College, London. Professor Dickenson's research is
focused on understanding the mechanisms of pain including how pain
can be controlled in both normal and patho-physiological conditions
and how to translate basic science to patients. He is an Honorary
Member of the British Pain Society, a member of the council of the
International Association for the Study of Pain, was a founding
member of the London Pain Consortium (Welcome Trust), and is
involved in many advisory boards.
The formation of the SAB underpins the next stage of the
Company's development and highlights its commitment to grow a
best-in-class network of partners - scientific, academic and
commercial.
OCTP Chief Scientific Officer, Doctor Valentino Parravicini
said:
"Our research ethos is to develop breakthrough therapies for
debilitating pain conditions with significant as yet unmet medical
needs. We are honoured and delighted to formalise our relationships
with Professors Robert Dworkin and Anthony Dickenson and Doctor
Giorgio Lambru as our SAB, whose combined experience and advice in
developing our drug candidates will, we are sure, be
invaluable."
The Directors of the Company accept responsibility for the
content of this announcement.
Enquiries:
Oxford Cannabinoid Technologies +44 (0)20 3034 2820
Holdings plc john@oxcantech.com
Dr John Lucas (CEO) clarissa@oxcantech.com
Clarissa Sowemimo-Coker (COO)
Cairn Financial Advisers
Emily Staples +44 (0)20 7213 0897
Jo Turner +44 (0) 20 7213 0885
Walbrook PR Limited +44 (0)20 7933 8780
Paul Vann +44 (0)7768 807631
Nick Rome oxcantech@walbrookpr.com
Harbor Access LLC (US/OTCB enquiries)
Jonathan Paterson +1 (203) 862 0492
Richard Leighton Richard.Leighton@harboraccessllc.com
About Oxford Cannabinoid Technologies Holdings Plc :
Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the
holding company of Oxford Cannabinoid Technologies Ltd ("OCT"), a
pharmaceutical company developing prescription cannabinoid
medicines for approval by key medicines regulatory agencies
worldwide and targeting the U$ multi-billion pain market (together
the "Group"). Cannabinoids are compounds found in the cannabis
plant that have been shown to have a range of therapeutic effects
on the body, including pain relief. The Group has a clearly defined
path to commercialisation, revenues and growth. The Group is
developing drug candidates through clinical trials to gain
regulatory approval (FDA/MHRA/EMA) that will enable medical
professionals to prescribe them with confidence.
The Group's portfolio aims to balance risk, value and time to
market, whilst ensuring market exclusivity around all its key
activities. The Group's lead compound, OCT461201, is a highly
potent and selective CB2 agonist and is being developed by OCT in a
solid oral dosage form. OCT is conducting pre-clinical testing and
development with clinical trials scheduled for Q1 2023. The Group's
product pipeline also uses a balanced drug product strategy that
employs both natural and synthetic compounds for the treatment of
rare diseases and includes chemically modified phytocannabinoids
with improved drug-like characteristics and a proprietary library
of cannabinoids.
OCTP operates a partnership model with external academic and
commercial partners.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward-looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDBGDSCUDDGDS
(END) Dow Jones Newswires
April 25, 2022 02:01 ET (06:01 GMT)
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
From Feb 2024 to Mar 2024
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
From Mar 2023 to Mar 2024